Christopher John Ong
Assistant Professor
Department of Surgery
Jack Bell Research Centre
Canada
Biography
Dr. Ong is the Assistant Professor, Department of Surgery, UBC, Assistant Professor, Department of Urologic Sciences, UBC, and Research Scientist, The Prostate Centre at VGH.
Research Interest
Dr. Ong and his colleagues identified a novel small molecule agonist of SHIP from the Papua New Guinea sponge, Dactylospongia elegans. Synthetic structural analogs possessing more potent biological activity were then identified. They have now devised an efficient, high yielding chemical synthetic protocol for production of this new family of compounds. Furthermore, they have performed extensive studies in wild-type and SHIP-deficient cells and in animal models of inflammation and cancer to demonstrate oral bioavailability, specificity, and efficacy of these compounds as a robust activator of SHIP and as a potent anti-inflammatory and anti-leukemia/lymphoma agent. Dr. Ong is also the scientific founder of Aquinox Pharmaceuticals Inc., a biopharmaceutical company focused on developing small molecule therapeutics for the treatment of cancer and inflammation.
Publications
-
Prognostic significance of the expression of nuclear eukaryotic translation initiation factor 5A2 in human melanoma. Khosravi S, Martinka M, Zhou Y, Ong CJ. Oncol Lett. 2016 Nov;12(5):3089-3100. Epub 2016 Aug 29. PMID: 27899968
-
Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Tam KJ, Dalal K, Hsing M, Cheng CW, Khosravi S, Yenki P, Tse C, Peacock JW, Sharma A, Chiang YT, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ. Oncotarget. 2017 Feb 7;8(6):9617-9633. doi: 10.18632/oncotarget.14168. PMID: 28038451
-
Enhanced Detection of Edema in Malignant Anterior Circulation Stroke (EDEMA) Score: A Risk Prediction Tool. Ong CJ, Gluckstein J, Laurido-Soto O, Yan Y, Dhar R, Lee JM. Stroke. 2017 Jul;48(7):1969-1972. doi: 10.1161/STROKEAHA.117.016733. Epub 2017 May 9. PMID: 28487333
